Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242956 | 1.00 | CA2 (0.46) | CA2ALOX12GABRA1GABRB2ALDH1A1 | |
| SCHEMBL20954046 | 0.84 | CA2 (0.44) | CA2ALOX12GABRA1GABRB2ALDH1A1 | |
| SCHEMBL20211348 | 0.84 | CA2 (0.44) | CA2ALOX12GABRA1GABRB2ALDH1A1 | |
| SCHEMBL1758933 | 0.80 | CA2 (0.38) | CA2ALOX12GABRA1GABRB2ALDH1A1 | |
| SCHEMBL1758934 | 0.80 | CA2 (0.38) | CA2ALOX12GABRA1GABRB2ALDH1A1 | |
| SCHEMBL14280786 | 0.76 | ALDH1A1 (0.49) | CA2ALOX12GABRA1GABRB2ALDH1A1 | |
| SCHEMBL14816945 | 0.74 | ALDH1A1 (0.51) | CA2ALOX12GABRA1GABRB2ALDH1A1 | |
| SCHEMBL6663440 | 0.74 | CA2 (0.40) | CA2ALOX12GABRA1GABRB2ALDH1A1 | |
| SCHEMBL16771251 | 0.73 | CA2 (0.48) | CA2ALOX12GABRA1GABRB2ALDH1A1 | |
| SCHEMBL361328 | 0.73 | CA2 (0.48) | CA2ALOX12GABRA1GABRB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363923-B1 | RHODIUM AND IRIDIUM COMPLEXES | MERCK PATENT GMBH (DE) | 2009-04-01 | — | — | EP | claimed |
| US-7125998-B2 | Rhodium and iridium complexes | MERCK PATENT GMBH (DE) | 2006-10-24 | — | — | US | claimed |
| EP-1562964-B1 | PALLADIUM AND PLATINUM COMPLEXES | MERCK PATENT GMBH (DE) | 2006-07-19 | — | — | EP | claimed |
| US-20040138455-A1 | Rhodium and iridium complexes | MERCK PATENT GMBH (DE) | 2004-07-15 | — | — | US | claimed |
| US-12635401-B2 | Metal complexes | UDC Ireland (IE) | 2026-05-19 | — | — | US | disclosed |
| EP-4069709-B1 | METAL COMPLEXES | UDC IRELAND LTD (IE) | 2025-04-23 | — | — | EP | disclosed |
| US-12250871-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2025-03-11 | — | — | US | disclosed |
| US-20240260448-A1 | Metal Complexes | UDC IRELAND LIMITED (IE) | 2024-08-01 | — | — | US | disclosed |
| US-11917901-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-20230056324-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2023-02-23 | — | — | US | disclosed |
| US-11404649-B2 | Electroluminescent bridged metal complexes for use in electronic devices | MERCK PATENT GMBH (DE) | 2022-08-02 | — | — | US | disclosed |
| US-20220209141-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2022-06-30 | — | — | US | disclosed |
| US-20050031900-A1 | Aromatic monomer-and conjugated polymer-metal complexes | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| US-20040138455-A1 | Rhodium and iridium complexes | MERCK PATENT GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
| US-6677268-B2 | A METAL COMPLEXES AS HYDROFORMYLATION CATALYST OF OLEFINICALLY UNSATURATED COMPOUNDS | INSTITUT FRANCAIS DU PETROLE (FR) | 2004-01-13 | — | — | US | disclosed |
| US-6617474-B2 | Reacting olefinically unsaturated compound with carbon monoxide and hydrogen in presence of polar phase comprising: a non-aqueous ionic liquid comprising quaternary ammonium and/or a quaternary phosphonium compound and catalyst; adding solvent | INSTITUT FRANCAIS DU PETROLE (FR) | 2003-09-09 | — | — | US | disclosed |
| US-20030055299-A1 | Catalyst based on cobalt and/or rhodium employed in a two-phase medium | INSTITUT FRANCAIS DU PETROLE (FR) | 2003-03-20 | — | — | US | disclosed |
| US-6469216-B2 | CO OR RH COMPLEX COORDINATED WITH A NITROGEN-CONTAINING LIGAND; QUATERNARY AMMONIUM OR PHOSPHONIUM IONIC SOLVENT | INSTITUT FRANCAIS DU PETROLE (FR) | 2002-10-22 | — | — | US | disclosed |
| US-20020099243-A1 | Process for the hydroformylation of olefinically unsaturated compounds in a non-aqueous ionic solvent | INSTITUT FRANCAIS DU PETROLE (FR) | 2002-07-25 | — | — | US | disclosed |
| US-20010039363-A1 | Process for hydroformylation using a catalyst based on cobalt and/or rhodium employed in a two-phase medium | INSTITUT FRANCAIS DU PETROLE (FR) | 2001-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12635401-B2 | Metal complexes | SCO2, SOD1, NR4A1 | CA2 265/4885ALOX12 3227/4885GABRA1 1347/4885 |
| US-20040138455-A1 | Rhodium and iridium complexes | RPIA, MPI, INPP5B | CA2 274/4885ALOX12 4507/4885GABRA1 4094/4885 |
| US-12250871-B2 | Metal complexes | AP1M1, SOD1, AP3M1 | CA2 697/4885ALOX12 2446/4885GABRA1 2853/4885 |
| US-20020099243-A1 | Process for the hydroformylation of olefinically unsaturated compounds in a non-aqueous ionic solvent | NUDT1, PHOSPHO1, SRSF6 | CA2 269/4885ALOX12 281/4885GABRA1 4669/4885 |
| US-20230056324-A1 | METAL COMPLEXES | MCU, IMMT, SOD1 | CA2 729/4885ALOX12 3394/4885GABRA1 2239/4885 |
| US-11404649-B2 | Electroluminescent bridged metal complexes for use in electronic devices | MCOLN2, MCOLN1, NCLN | CA2 2624/4885ALOX12 2333/4885GABRA1 3682/4885 |
| US-20220209141-A1 | METAL COMPLEXES | AP1M1, SOD1, AP3M1 | CA2 697/4885ALOX12 2446/4885GABRA1 2853/4885 |
| US-11917901-B2 | Metal complexes | MCOLN2, MCOLN1, AP1M1 | CA2 1501/4885ALOX12 1454/4885GABRA1 4370/4885 |
| US-20240260448-A1 | Metal Complexes | SOD1, AP1M1, AP3M1 | CA2 898/4885ALOX12 2498/4885GABRA1 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.